← Eichor
Condition: Non Metastatic Colorectal Cancer Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Non Metastatic Colorectal Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 · 40 location(s) · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · NCT06625775Liver Transplantation for Non-Resectable Colorectal Liver Metastasis
NA · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT05185245Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
Phase N/A · 1 location(s) · University of Missouri-Columbia · NCT02838836Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Phase 1/Phase 2 · 27 location(s) · Institut de Recherches Internationales Servier · NCT05786924A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Phase 1 · 34 location(s) · Incyte Corporation · NCT06179160Interest of the Immunoscore® as a Post-operative Complementary Tool for the Detection of the Risk of Recurrence in Patie
NA · 2 location(s) · Hospital St. Joseph, Marseille, France · NCT04938986Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
Phase 1 · 1 location(s) · Novartis Pharmaceuticals · NCT07630961This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Tor
Phase 1 · 3 location(s) · Zumutor Biologics Inc. · NCT06451497A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Phase 1/Phase 2 · 26 location(s) · Frontier Medicines Corporation · NCT06244771A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Phase 1/Phase 2 · 1 location(s) · Blueprint Medicines Corporation · NCT07629960A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Tasca Therapeutics · NCT07030257TheraSphere Japan Pre-Market Study
NA · 4 location(s) · Boston Scientific Corporation · NCT07377487A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor
Phase 1/Phase 2 · 10 location(s) · A2 Biotherapeutics Inc. · NCT06682793First in Human Study of SIM0610 in Solid Tumors
Phase 1 · 7 location(s) · Jiangsu Simcere Pharmaceutical Co., Ltd. · NCT07348211Preoperative Ketogenic Diet for Reduction of Hepatic Steatosis
NA · 1 location(s) · Anton Skaro · NCT05884723Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Phase 1/Phase 2 · 6 location(s) · Revolution Medicines, Inc. · NCT07397338A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangement
Phase 1/Phase 2 · 165 location(s) · Turning Point Therapeutics, Inc. · NCT03093116Early Detection of Advanced Adenomas and Colorectal Cancer
Phase N/A · 6 location(s) · City of Hope Medical Center · NCT06342440A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patien
Phase 1/Phase 2 · 1 location(s) · Shenzhen Ionova Life Sciences Co., Ltd. · NCT07610798A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Phase 1 · 12 location(s) · Alterome Therapeutics, Inc. · NCT06835569Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C M
Phase 1/Phase 2 · 53 location(s) · Revolution Medicines, Inc. · NCT06128551SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Phase N/A · 68 location(s) · Massive Bio, Inc. · NCT03452774A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Phase 1 · 12 location(s) · Aktis Oncology, Inc. · NCT07020117A Study of NX-1607 in Adults With Advanced Malignancies
Phase 1 · 17 location(s) · Nurix Therapeutics, Inc. · NCT05107674A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colo
Phase 2 · 1 location(s) · Blokhin's Russian Cancer Research Center · NCT06978400A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
Phase 1 · 2 location(s) · Chongqing Precision Biotech Co., Ltd · NCT06043466Botensilimab, Balstilimab, and SBRT in Colorectal Cancer
EARLY_Phase 1 · 1 location(s) · Massachusetts General Hospital · NCT07128355Impact of Aerobic Exercise on the Anticancer Immune Response in Patients Receiving Cancer Treatment
NA · 2 location(s) · Université de Sherbrooke · NCT06911970A Study of YL202 in Patients With Advanced Solid Tumors
Phase 2 · 1 location(s) · MediLink Therapeutics (Suzhou) Co., Ltd. · NCT07202364
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.